cilomilast has been researched along with amlodipine in 3 studies
| Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (amlodipine) | Trials (amlodipine) | Recent Studies (post-2010) (amlodipine) |
|---|---|---|---|---|---|
| 162 | 13 | 42 | 4,200 | 1,504 | 1,671 |
| Protein | Taxonomy | cilomilast (IC50) | amlodipine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | 1.2 | |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | 0.4 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.602 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.8 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 2.898 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 5.521 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 2.7 | |
| Potassium channel subfamily K member 2 | Bos taurus (cattle) | 0.43 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for cilomilast and amlodipine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |